GMK Extension
Medacta International SA · Decision date Sep 15, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision for K262057, trade name GMK Extension, on September 15, 2026, with the application received June 18, 2026. The applicant is Medacta International SA; the device falls under 21 CFR 888.3560, Class II, product code JWH, in the orthopedic specialty. This is a traditional 510(k) clearance, not a PMA approval.
The submission is a line extension adding GMK Sphere FULL PE FLEX and FLEX E-CROSS tibias, described as sterile, single-use implants replacing the tibial plateau, in UHMWPE and vitamin E crosslinked UHMWPE versions across 15 thickness sizes, plus the GMK Primary Oblique Extension Stem. Substantial equivalence is claimed to primary predicate K131310 and additional predicates K202022, K090988, K211004, K133630 and K223548. The source does not state clinical performance data or the basis for the stem's comparison.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Orthopedic
- Decision date
- Sep 15, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K262057
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Medacta International SA
- Product code
- JWH
- Decision code
- SESE
- Decision date
- Sep 15, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Prosthesis, Knee, Patellofemorotibial, Semi-Constrained, Cemented, Polymer/Metal/Polymer.
- Applicant
- Medacta International SA
- Product code
- JWH
- FDA device class
- 2
FDA decision timeline
K262057 received
Application receipt date recorded by FDA.
K262057 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code JWH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MicroPort Total Knee SystemK263065 | Suzhou Microport Orthorecon Co., Ltd. | 510(k) clearance | Oct 29, 2026 | FDA |
GSPE SpacerK260063 | The General Hospital Corporation, d/b/a Massachusetts | 510(k) clearance | Sep 11, 2026 | FDA |
| Suzhou Microport Orthorecon Co., Ltd. | 510(k) clearance | Sep 10, 2026 | FDA | |
| B-One Ortho, Corp. | 510(k) clearance | Sep 8, 2026 | FDA | |
ATTUNE Revision Knee SystemK262130 | Depuy Orthopaedics, Inc. | 510(k) clearance | Sep 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medacta International SA
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Castel San Pietro
Sources and methodology
- Original FDA record: K262057
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


